Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncogenic snoRNA <i>SNORD78</i> fuels colorectal cancer by protecting the m<sup>6</sup>A reader IMP2 to enhance phospholipid metabolism.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Feasibility and Process Evaluation of CArdiac Brief INtervention (CABIN) in Patients with ST-Elevation Myocardial Infarction: A Mixed-Method, Pilot Randomised Controlled Trial.

European journal of cardiovascular nursing·2026
Same author

Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials.

Advances in therapy·2026
Same author

Prediction of hospitalisation in young children with pneumonia in Malawi: A machine learning-based approach.

PLoS medicine·2026
Same author

The United Kingdom National Programme of DCD heart transplantation: Timings, techniques, feasibility, and outcomes with abdominal normothermic regional perfusion.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Evaluating the implementation and impact of the HEart faiLure carer support Programme (HELP) in the United Kingdom: A study protocol for a multi-centre, mixed-method, implementation study.

PloS one·2026

Related Experiment Video

Updated: Jul 6, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.2K

SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?

Patrick Savage1, Lana Dixon1, David Grieve2

  • 1From the Royal Victoria Hospital Cardiology Department.

Cardiology in Review
|January 8, 2024
PubMed
Summary

Sodium-glucose cotransport 2 inhibitors offer significant cardioprotective benefits for heart failure patients. Current research explores mechanisms beyond glucose lowering and fluid excretion to understand these potent effects.

Keywords:
SGLT2 inhibitorscardioprotectiveheart failuremechanisms

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

10.7K
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

1.5K

Related Experiment Videos

Last Updated: Jul 6, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.2K
Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

10.7K
Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

1.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Translational Medicine

Background:

  • Sodium-glucose cotransport 2 (SGLT2) inhibitors are now guideline-directed therapy for heart failure.
  • Their benefits span the spectrum of left ventricular dysfunction.
  • Understanding their precise mechanisms of action is crucial.

Purpose of the Study:

  • To review the cardioprotective benefits of SGLT2 inhibitors shown in major clinical trials.
  • To summarize current theories on their mechanisms of action, integrating clinical and laboratory data.

Main Methods:

  • Review of landmark clinical trials (e.g., dapagliflozin, empagliflozin) in heart failure.
  • Synthesis of evidence from clinical and preclinical studies on SGLT2 inhibitor mechanisms.
  • Exploration of proposed pathways beyond glycosuria and natriuresis.

Main Results:

  • SGLT2 inhibitors demonstrate broad cardioprotective effects in heart failure.
  • Established mechanisms include improved glucose homeostasis, blood pressure control, and natriuresis.
  • Emerging evidence suggests additional pathways: anti-inflammatory effects, improved myocardial sodium handling, profibrotic modulation, and autophagy induction.

Conclusions:

  • SGLT2 inhibitors represent a major advance in heart failure pharmacotherapy.
  • Their benefits likely result from a combination of direct cardiac effects and metabolic improvements.
  • Further research is needed to fully elucidate the complex mechanisms underlying their efficacy.